TY - JOUR
T1 - Difference in outcomes following allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndromes
AU - Yanada, Masamitsu
AU - Mizuno, Shohei
AU - Yamasaki, Satoshi
AU - Harada, Kaito
AU - Konuma, Takaaki
AU - Tamaki, Hiroya
AU - Shingai, Naoki
AU - Uchida, Naoyuki
AU - Ozawa, Yukiyasu
AU - Tanaka, Masatsugu
AU - Onizuka, Makoto
AU - Sawa, Masashi
AU - Nakamae, Hirohisa
AU - Shiratori, Souichi
AU - Matsuoka, Ken ichi
AU - Eto, Tetsuya
AU - Kawakita, Toshiro
AU - Maruyama, Yumiko
AU - Ichinohe, Tatsuo
AU - Kanda, Yoshinobu
AU - Atsuta, Yoshiko
AU - Aoki, Jun
AU - Yano, Shingo
N1 - Publisher Copyright:
© 2021 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2021
Y1 - 2021
N2 - To evaluate whether outcomes following allogeneic hematopoietic cell transplantation differ according to disease type, a three-way comparison for patients with de novo acute myeloid leukemia (AML) (n = 3318), AML evolving from myelodysplastic syndromes (MDS) (n = 208), and MDS with excess blasts (MDS-EB) (n = 994) was performed. The 5-year probabilities of overall survival (OS) for de novo AML, AML evolving from MDS, and MDS-EB were 60%, 42%, and 41% (p < 0.001), respectively. Multivariate analysis revealed that, compared to de novo AML, AML evolving from MDS was associated with a higher risk of NRM (p = 0.030) and MDS-EB with a higher risk of relapse (p < 0.001), both leading to lower OS (p = 0.010 and p < 0.001, respectively). These findings demonstrate inter-disease differences in post-transplant outcomes and highlight the needs to reduce NRM for AML evolving from MDS and to reduce relapse for MDS-EB.
AB - To evaluate whether outcomes following allogeneic hematopoietic cell transplantation differ according to disease type, a three-way comparison for patients with de novo acute myeloid leukemia (AML) (n = 3318), AML evolving from myelodysplastic syndromes (MDS) (n = 208), and MDS with excess blasts (MDS-EB) (n = 994) was performed. The 5-year probabilities of overall survival (OS) for de novo AML, AML evolving from MDS, and MDS-EB were 60%, 42%, and 41% (p < 0.001), respectively. Multivariate analysis revealed that, compared to de novo AML, AML evolving from MDS was associated with a higher risk of NRM (p = 0.030) and MDS-EB with a higher risk of relapse (p < 0.001), both leading to lower OS (p = 0.010 and p < 0.001, respectively). These findings demonstrate inter-disease differences in post-transplant outcomes and highlight the needs to reduce NRM for AML evolving from MDS and to reduce relapse for MDS-EB.
KW - Acute myeloid leukemia
KW - allogeneic hematopoietic cell transplantation
KW - myelodysplastic syndrome
UR - http://www.scopus.com/inward/record.url?scp=85111882442&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85111882442&partnerID=8YFLogxK
U2 - 10.1080/10428194.2021.1961242
DO - 10.1080/10428194.2021.1961242
M3 - Article
C2 - 34348554
AN - SCOPUS:85111882442
SN - 1042-8194
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
ER -
